How we diagnose and treat hereditary transthyretin-mediated amyloidosis with polyneuropathy in the Balkan region: an expert opinion - Scorecard - MDSpire
Advertisement
How we diagnose and treat hereditary transthyretin-mediated amyloidosis with polyneuropathy in the Balkan region: an expert opinion
Clinical Scorecard: Diagnosis and Management of Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy in the Balkan Area: Insights from Experts
At a Glance
Category
Detail
Condition
Hereditary transthyretin-mediated amyloidosis with polyneuropathy
Key Mechanisms
Genetic mutations in the TTR gene leading to amyloid deposits in organs and tissues.
Target Population
Individuals with hereditary transthyretin-mediated amyloidosis, particularly in Balkan countries.
Care Setting
Multidisciplinary expert panels and healthcare systems in Bulgaria, Croatia, Serbia, and Slovenia.
Key Highlights
High rate of early diagnosis (95%) in Bulgaria due to systematic screening.
Delays in diagnosis noted in other Balkan countries due to insufficient awareness.
Genetic testing is fundamental and routinely performed across all countries.
Clinical heterogeneity in disease onset and severity observed among patients.
Interdisciplinary collaboration and awareness campaigns are key areas for improvement.
Guideline-Based Recommendations
Diagnosis
Systematic screening programs for affected families.
Genetic testing for TTR mutations in patients with unexplained progressive polyneuropathy.
Management
Early diagnosis and treatment initiation to improve patient outcomes.
Monitoring & Follow-up
Regular follow-up for asymptomatic carriers identified through genetic testing.
Risks
Potential delays in diagnosis due to low awareness among healthcare professionals.
Patient & Prescribing Data
Individuals with hereditary transthyretin-mediated amyloidosis with polyneuropathy in the Balkan region.
Access to therapies varies by country, with some regions facing reimbursement issues.
Clinical Best Practices
Enhance interdisciplinary collaboration among specialists.
Implement awareness campaigns targeting various healthcare professionals.
Utilize genetic testing as a standard diagnostic tool.
